Department of Emergency, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Department of Emergency, Dan Zhou People's Hospital, Dan Zhou, China.
Front Endocrinol (Lausanne). 2022 Apr 28;13:879443. doi: 10.3389/fendo.2022.879443. eCollection 2022.
Thyroid hormones widely affect the cardiovascular system, but the effects of mild thyroid dysfunction on the clinical prognosis of patients with acute ST segment elevation myocardial infarction (STEMI) remains unclear. Our aims were to analyze the relations between mild thyroid dysfunction at admission and clinical outcomes in Chinese patients with STEMI.
A total of 1,176 STEMI patients with the available data of thyroid function and follow-up were analyzed, including 348 patients with mild thyroid dysfunction [subclinical hypothyroidism (n=81), hyperthyroidism (SHyper) (n=51), and low triiodothyronine syndrome (LT3S) (n=216)] and 828 patients with euthyroid function. During a median 4.4-year follow-up, in-hospital mortality, cardiac and all-cause mortalities were subsequently compared among the four groups.
Compared with the euthyroid group, STEMI patients in the SHyper and LT3S groups faced obviously increased risks of in-hospital death [odds ratio (OR): 5.007, 95% confidence interval (CI): 1.246-20.124, p = 0.023 and OR: 2.491, 95% CI: 1.054-5.887, p = 0.037, respectively) even after adjustment for various confounding factors. During a median 4.4-year follow-up, STEMI patients with LT3S at baseline had higher cardiovascular mortality [hazard ratio (HR): 1.880, 95% CI: 1.178-2.998, p = 0.008] and all-cause mortality HR: 1.647, 95% CI: 1.072-2.531, p = 0.023] than those with euthyroid at baseline, whereas no significantly increased mortality was found for STEMI patients with SCH and SHyper at baseline.
STEMI patients with SHyper at admission had increased risk of in-hospital mortality, and STEMI patients with LT3S at baseline had worse prognosis and higher incidences of in-hospital mortality and cardiovascular and all-cause deaths compared with euthyroid patients.
甲状腺激素广泛影响心血管系统,但轻度甲状腺功能障碍对急性 ST 段抬高型心肌梗死(STEMI)患者临床预后的影响尚不清楚。我们的目的是分析中国 STEMI 患者入院时轻度甲状腺功能障碍与临床结局的关系。
共分析了 1176 例有甲状腺功能和随访资料的 STEMI 患者,其中 348 例为轻度甲状腺功能障碍患者(亚临床甲状腺功能减退症[SCH]81 例,甲状腺功能亢进症[甲亢]SHyper 51 例,低三碘甲状腺原氨酸综合征[LT3S]216 例),828 例为甲状腺功能正常患者。在中位随访 4.4 年后,比较四组患者的院内死亡率、心源性死亡率和全因死亡率。
与甲状腺功能正常组相比,SHyper 组和 LT3S 组 STEMI 患者院内死亡风险明显增加[优势比(OR):5.007,95%置信区间(CI):1.246-20.124,p = 0.023 和 OR:2.491,95% CI:1.054-5.887,p = 0.037,分别],即使在校正了各种混杂因素后也是如此。在中位随访 4.4 年期间,基线时患有 LT3S 的 STEMI 患者心血管死亡率[风险比(HR):1.880,95%CI:1.178-2.998,p = 0.008]和全因死亡率 HR:1.647,95%CI:1.072-2.531,p = 0.023]均高于基线时甲状腺功能正常的患者,而基线时患有 SCH 和 SHyper 的 STEMI 患者的死亡率未见明显升高。
入院时患有甲亢的 STEMI 患者院内死亡率增加,而基线时患有 LT3S 的 STEMI 患者与甲状腺功能正常的患者相比,预后较差,院内死亡率及心血管和全因死亡率较高。